CD34 + cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance - Associated phenotypes

Clinical Cancer Research

Volumn 10, Issue 22, 2004, Pages 7599-7606

  Suárez, Lilia ^a,b   Vidriales, María Belén ^a,b   García Laraña, José ^d   Sanz, Guillermo ^e   Moreno, María José ^f   López, Antonio ^c   Barrena, Susana ^b   Martínez, Rafael ^g   Tormo, Mar ^h   Palomera, Luis ⁱ   Lavilla, Esperanza ^j   López Berges, Ma Consuelo ^a   De Santiago, María ^c   Pérez De Equiza, M Encarnación ^k   San Miguel, Jesús F ^a,b   Orfao, Alberto ^b,c  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h Department of Hematology   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^j HOSPITAL XERAL CALDE   (Spain)

^k Universidad Pública de Navarra   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CANCER RESISTANCE; CELL SUBPOPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANTIGENS, CD34; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BONE MARROW CELLS; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; MYELODYSPLASTIC SYNDROMES; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 9344268821     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0598     Document Type: Article

References (49)

1. San Miguel JF, Sanz GF, Vallespí T, del Cañizo MC, Sanz MA. Myelodysplastic syndromes. Crit Rev Oncol-Hematol 1996;23:57-93.
2. Domenico D, Aiello A, Soligo D, et al. Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 1992;5:1291-8.
3. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996;88:4275-87.
4. Parker JE, Fishlock KL, Mijovic A, et al. Low-risk myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol 1998;103:1075-82.
5. Davis RE, Greenberg PL. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. Leuk Res 1998;22:767-77.
6. Tsoplou P, Kouraklis-Symeonidis A, Thanopoulou E, et al. Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in 'good' versus 'poor' prognosis patients and correlation with apoptosis-related genes. Leukemia (Baltimore) 1999; 13:1554-63.
7. Parker JE, Mufti GJ, Rasool F, et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000;96:3932-8.
8. Berger G, Hunault-Berger M, Rachieru P, et al. Increased apoptosis in mononucleated cells but not in CD34 (+) cells in blastic forms of myelodysplastic syndromes. Hematol J 2001;2:87-96.
9. Boudard D, Vasselon C, Bertheas MF, et al. Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. Am J Hematol 2002;70:115-25.
10. Huh YO, Jilani I, Estey E, et al. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. Leukemia (Baltimore) 2002;16:2249-52.
11. Lin CW, Manshouri T, Jilani I, et al. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res 2002;26:551-9.
12. Pecci A, Travaglino E, Klersy C, Invernizzi R. Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic bone marrow. Acta Haematol (Basel) 2003;109:29-34.
13. Macedo A, Orfao A, González M, et al. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia (Baltimore) 1995;9:993-8.
14. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev Cancer 2002;2:48-58.
15. Igney FH, Krammer PH. Death and anti-death: tumor resistance to apoptosis. Nature Rev Cancer 2002;2:277-88.
16. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003; 22:7414-30.
17. Bradbury DA, Russell NH. Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells. Br J Haematol 1995;91:374-9.
18. Suárez L, Vidriales B, García-Laraña J, et al. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia. Haematologica 2001;86:1287-95.
19. Tothova E, Fricova M, Stecova N, Kafkova A, Elbertova A. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma (Bratisl) 2002;49:141-4.
20. Wuchter C, Karawajew L, Ruppert V, et al. Clinical significance of CD95, bcl-2 and bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia (Baltimore) 1999;13:1943-53.
21. Del Poeta G, Venditti A, Del Principe MI, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003;101:2125-31.
22. Takeshita A, Shinjo K, Ohnishi K, Ohno R. Expression of multidrug resistance P-glycoprotein in myeloid progenitor cells of different phenotype: comparison between normal bone marrow cells and leukaemia cells. Br J Haematol 1996;93:18-21.
23. List AF. The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia (Baltimore) 1996;10: 937-42.
24. List AF, Spier CM, Cline A, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol 1991;78:28-34.
25. Sonneveld P, van Dongen JJ, Hagemeijer A, et al. High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia (Baltimore) 1993;7:963-9.
26. Lepelly P, Soenen V, Preudhomme C, et al. Expression of the multidrug resistance p-glycoprotein and its relationship to hematological characteristic and response to treatment in myelodysplastic syndromes. Leukemia (Baltimore) 1994;8:998-1004.
27. Poulain S, Leppelly P, Preudhomme C, et al. Expression of multidrug resistance-associated protein in myelodysplastic syndromes. Br J Haematol 2000;110:591-8.
28. Macedo A, San Miguel JF, Vidriales MB, et al. Phenotypic changes in acute myeloid leukemia: implications in the detection of minimal residual disease. J Clin Pathol 1996;49:15-8.
29. Raspadori D, Lauria F, Ventura MA, et al. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. Leuk Res 1997;21:603-7.
30. Konopleva M, Zhao S, Hu W, et al. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol 2002;118:521-34.
31. Porwit-MacDonald A, Ivory K, Wilkinson S, et al. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia (Baltimore) 1995;9:1191-8.
32. Drach D, Zhao S, Drach J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992;80:2729-34.
33. Legrand O, Perrot JY, Tang R, et al. Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal pheripheral blood and bone marrow haemopoietic cells. Br J Haematol 1996;94:23-33.
34. Beck WT, Grogan TM. Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins. Leukemia (Baltimore) 1997;11:1107-9.
35. Legrand O, Simonin G, Zittoun R, Marie JP. Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. Leukemia (Baltimore) 1998;12: 1367-74.
36. Marie JP, Legrand O, Perrot JY, et al. Measuring multidrug resistance expression in human malignancies: elaboration of consensus recommendations. Semin Hematol 1997;4(Supp 5):63-71.
37. Parker JE, Mufti GJ. The role of apoptosis in the pathogenesis of the myelodysplastic syndromes. Int J Hematol 2001;73:416-28.
38. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of the acute myeloid leukaemia. Ann Intern Med 1985;103:620-9.
39. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
40. Greenberg P, Cox C, Lebeau MM, et al. International scoring system for evaluation prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
41. Sanz GF, Sanz MA, Vallespi T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989;74:395-408.
42. Kappelmayer J, Gratama JW, Karaszi E, et al. Flow cytometric detection of intracellular myeloperoxidase, CD3 and CD79a. Interaction between monoclonal antibody clones, fluorochromes and sample preparation protocols. J Immunol Methods 2000;242:53-65.
43. Shetty V, Hussaini S, Broady-Robinson L, et al. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood 2000;96:1388-92.
44. -ve bone marrow cell compartments from patients with myelodysplastic syndromes (MDS). Leukemia (Baltimore). 2004;18:1311-13.
45. Leppelly P, Poulain S, Grardel N, et al. Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes. Leuk Lymphoma 1998;29:547-51.
46. Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000;247:521-34.
47. Abbott BL, Colapietro AM, Barnes Y, et al. Low levels of ABCG2 expression in adult AML blast samples. Blood 2002;100:4594-601.
48. Nakanishi T, Karp JE, Tan M, et al. Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res 2003;9:3320-8.
49. Abbott BL. ABCG2 (BCRP) expression in normal and malignant hematopoietic cells. Hematol Oncol 2003;21:115-30.